Nona Biosciences

Nona Biosciences is a global biotechnology company committed to providing a total solution for partners worldwide, from academies, biotech startups to biopharma giants. The integrated antibody discovery services range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging the advantages of Harbour Mice® platforms and the experienced therapeutic antibody discovery team. Harbour Mice® generates fully human monoclonal antibodies in two heavy and two light chains (H2L2) format, as well as heavy chain only (HCAb) format. Integrating Harbour Mice® and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs by diversified partnership strategies including co-discovery, platform and antibody discovery, and platform license. The values of the antibody discovery platforms and flexible partnership models have been well validated by more than 50 industry and academic partners within over 200 projects.

Pioneering Medicines

Pioneering Medicines, Flagship Pioneering’s in house drug discovery and development unit, is dedicated to conceiving and developing a broad portfolio of life-changing treatments for patients built from Flagship’s innovative platforms. Harnessing the drug development expertise of its team together with the power of Flagship’s multiple scientific platforms, Pioneering Medicines explores and identifies new product concepts and then works jointly with Flagship’s companies to form integrated teams that advance medicines through robust discovery and early clinical development. Pioneering Medicines also partners with external collaborators across biopharma throughout the R&D process, applying its unique approach to the R&D priorities of partners through highly co-creative relationships. The team leads Flagship’s Innovation Supply Chain Partnerships with Novo Nordisk and Pfizer to speed innovation in drug development and bring novel therapies to patients, as well as a partnership with the Cystic Fibrosis Foundation to develop therapeutics that address the unmet needs of people living with cystic fibrosis.

Nuvalent, Inc.

Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs. To learn more, visit www.nuvalent.com.

KalVista Pharmaceuticals, Inc.

For nearly a decade, KalVista Pharmaceuticals has been focused on addressing the critical unmet needs of those living with hereditary angioedema (HAE). With more than 250 employees worldwide, we leverage our team’s vast knowledge and expertise across all aspects of research, development, and commercialization to redefine the future of HAE treatment and advance global care for those who need it most.

Korro Bio, Inc.

Korro Bio was founded to turn extraordinary scientific insights into life-altering new treatments for patients. We harness the body’s natural RNA editing machinery to make precise, single-base RNA edits to modulate protein function, addressing the medical needs of patients. Our mission is to rewrite the future for patients living with debilitating disease by repairing the underlying genetic cause.